Provided by Tiger Fintech (Singapore) Pte. Ltd.

Krystal Biotech Inc.

162.29
-3.8700-2.33%
Pre-market: 162.790.5000+0.31%07:15 EDT
Volume:343.44K
Turnover:56.08M
Market Cap:4.69B
PE:54.10
High:167.21
Open:166.59
Low:161.71
Close:166.16
Loading ...

Company Profile

Company Name:
Krystal Biotech Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
275
Office Location:
2100 Wharton Street,Suite 701,Pittsburgh,Pennsylvania,United States
Zip Code:
15203
Fax:
- -
Introduction:
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Directors

Name
Position
Krish S. Krishnan
President and Chief Executive Officer, Chairman of the Board of Directors
Suma M. Krishnan
Founder, Chief Operating Officer and Director
Daniel S. Janney
Director
Dino A. Rossi
Director
Kirti Ganorkar
Director
Rockford Douglas Norby
Director

Shareholders

Name
Position
Krish S. Krishnan
President and Chief Executive Officer, Chairman of the Board of Directors
Suma M. Krishnan
Founder, Chief Operating Officer and Director